We continue our series of posts inspired by Drug Hunter’s “Molecules of the Month” (drughunter.com)!

A recently highlighted molecule by Drug Hunter is FHD-286 — an orally active, selective, allosteric, and highly potent inhibitor of BRG1 (SMARCA4)/BRM (SMARCA2) ATPase, which is now in Phase I trials in metastatic uveal melanoma treating.

Chemspace offers a selected set of analogs of this drug candidate from our in-stock and Make-On-Demand catalogs. Exploring the vast chemical space could lead to unexpected insights and promising results!

Follow the link to uncover the molecules we have prepared for you!

The BAF (BRG1/BRM-associated factor) family, a group of chromatin remodeling complexes, plays a crucial role in regulating chromatin accessibility and gene expression. BAF complex activities are integral to various immunologic responses, and previous research highlights its role in antitumor immunity regulation. BRM/BRG1 ATPase, the catalytic subunit of the BAF complex, significantly contributes to enzymatic activity in chromatin remodeling. In pre-clinical trials, ATPase inhibitor FHD-286 demonstrated anti-tumor efficacy across diverse malignancies, spanning both hematologic and solid tumors. This promising drug candidate exhibits the potential to sensitize tumors to immune checkpoint inhibition, introducing a novel combination approach for cancer immunotherapy.

Go to chem-space.com/search to find in-stock and Make-on-Demand molecules of your interest!